Receptos Gains 2%, CEO Touts Phase II Trials By: Benzinga via Benzinga February 27, 2015 at 11:58 AM EST Receptos Inc (NASDAQ: RCPT) gained more than 2 percent after its chief executive said recent data on a promising colitis drug ... Read More >>